{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:36Z","timestamp":1790474136608,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"KAKENHI","award":["25290053"],"award-info":[{"award-number":["25290053"]}]},{"name":"KAKENHI","award":["16H04706"],"award-info":[{"award-number":["16H04706"]}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation (YS)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"crossref","award":["14-24617"],"award-info":[{"award-number":["14-24617"]}],"id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"crossref"}]},{"name":"P-DIRECT (YS)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.canlet.2016.10.020","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T18:50:37Z","timestamp":1476989437000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis"],"prefix":"10.1016","volume":"385","author":[{"given":"Kosuke","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Osada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-1630","authenticated-orcid":false,"given":"Yuko","family":"Murakami-Tonami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.10.020_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J.\u00a0Cell Physiol."},{"key":"10.1016\/j.canlet.2016.10.020_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.canlet.2016.10.020_bib3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.10.020_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.10.020_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/thoraxjnl-2013-204161","article-title":"Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis","volume":"69","author":"Reid","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.canlet.2016.10.020_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2016.10.020_bib7","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib8","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","article-title":"The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP","volume":"122","author":"Huang","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.10.020_bib10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0092-8674(02)00824-3","article-title":"Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines","volume":"110","author":"Tapon","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.10.020_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ncb2303","article-title":"The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal","volume":"13","author":"Zhao","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.020_bib12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1101\/gad.1536007","article-title":"Hippo signaling in organ size control","volume":"21","author":"Pan","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2016.10.020_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The hippo signaling pathway in development and cancer","volume":"19","author":"Pan","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2016.10.020_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrc2070","article-title":"The Salvador-Warts-Hippo pathway \u2013 an emerging tumour-suppressor network","volume":"7","author":"Harvey","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.10.020_bib15","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1073\/pnas.0605579103","article-title":"Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon","volume":"103","author":"Overholtzer","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","author":"Zender","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.10.020_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ceb.2009.09.010","article-title":"Herding Hippos: regulating growth in flies and man","volume":"21","author":"Badouel","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.020_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib19","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/carcin\/bgn200","article-title":"YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation","volume":"29","author":"Yokoyama","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2016.10.020_bib20","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nrc1751","article-title":"Statins and cancer prevention","volume":"5","author":"Demierre","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.10.020_bib21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1164\/ajrccm.157.5.9709020","article-title":"Lovastatin induces apoptosis in malignant mesothelioma cells","volume":"157","author":"Rubins","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2016.10.020_bib22","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1073\/pnas.1319190110","article-title":"Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib23","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1074\/jbc.M110.193714","article-title":"Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44","volume":"286","author":"Mandal","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.10.020_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: from adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.020_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Zoller","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.10.020_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/path.1400","article-title":"Extracellular matrix remodelling: the role of matrix metalloproteinases","volume":"200","author":"Stamenkovic","year":"2003","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.canlet.2016.10.020_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2016.10.020_bib28","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib30","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1073\/pnas.1004900107","article-title":"Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes","volume":"107","author":"Taube","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.189601","article-title":"The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44","volume":"15","author":"Morrison","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2016.10.020_bib32","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.18632\/oncotarget.3095","article-title":"Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2016.10.020_bib33","first-page":"82","article-title":"CD44 isoforms in metastatic cancer","volume":"14","author":"Ponta","year":"1994","journal-title":"Invasion Metastasis"},{"key":"10.1016\/j.canlet.2016.10.020_bib34","first-page":"3337","article-title":"Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium","volume":"54","author":"Dall","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib35","first-page":"145","article-title":"Splice variant expression of CD44 in patients with breast and ovarian cancer","volume":"8","author":"Sanchez Lockhart","year":"2001","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2016.10.020_bib36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JTO.0b013e318200f447","article-title":"The use of pleural fluid sCD44v6\/std ratio for distinguishing mesothelioma from other pleural malignancies","volume":"6","author":"Porcel","year":"2011","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.canlet.2016.10.020_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1073\/pnas.0911427107","article-title":"Hippo signaling is a potent in\u00a0vivo growth and tumor suppressor pathway in the mammalian liver","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib38","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/5965","article-title":"Mice deficient of LATS1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction","volume":"21","author":"St John","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2016.10.020_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/carcin\/bgq254","article-title":"YAP is a candidate oncogene for esophageal squamous cell carcinoma","volume":"32","author":"Muramatsu","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2016.10.020_bib40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.10.020_bib41","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/0008-5472.CAN-13-3569","article-title":"Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties","volume":"74","author":"Song","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ncb2936","article-title":"Metabolic control of YAP and TAZ by the mevalonate pathway","volume":"16","author":"Sorrentino","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.020_bib43","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2016.10.020_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2016.10.020_bib46","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.020_bib47","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2016.10.020_bib48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2016.10.020_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.10.020_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:55:04Z","timestamp":1589702104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516306401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":50,"alternative-id":["S0304383516306401"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}